Glimepiride Sandoz

Glimepiride Sandoz is a generic oral tablet containing the active ingredient glimepiride, a sulfonylurea‑type antidiabetic agent. It is manufactured for the European market and prescribed for adults with type 2 diabetes mellitus to help control blood glucose. The product is available only by prescription, is taken by mouth, and follows EU quality standards for solid oral dosage forms. Each tablet provides a consistent dose and includes standard excipients.

Glimepiride Sandoz is indicated for the oral management of hyperglycemia in patients with type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient.

- As monotherapy in patients newly diagnosed with type 2 diabetes. - In combination with metformin when glycemic control is not achieved with metformin alone. - As part of a fixed‑dose combination regimen with other oral antidiabetic agents. - To improve fasting and post‑prandial blood glucose levels. - For use in adults whose renal function is stable and within recommended limits.

The safety profile of glimepiride includes a range of observed adverse events, most of which are dose‑related and reversible upon discontinuation.

Common: - Mild hypoglycemia. - Weight gain. - Nausea or abdominal discomfort. - Headache.

Serious: - Severe hypoglycemia with loss of consciousness. - Allergic skin reactions (rash, urticaria). - Liver enzyme elevations or hepatitis.

Before prescribing Glimepiride Sandoz, clinicians should evaluate patient-specific factors and monitor for conditions that may increase the risk of adverse outcomes.

- Assess renal and hepatic function; dose adjustment may be required. - Review history of hypersensitivity to sulfonylureas. - Caution in elderly patients due to higher hypoglycemia risk. - Avoid use in patients with diabetic ketoacidosis. - Monitor for signs of hypoglycemia, especially when meals are missed. - Educate patients on recognizing and managing low blood glucose.

Glimepiride can interact with several medicines, altering its glucose‑lowering effect or increasing the risk of side effects.

Avoid: - Concurrent use with other sulfonylureas or meglitinides (additive hypoglycemia risk). - Strong CYP2C9 inhibitors such as fluconazole or amiodarone (increase glimepiride levels). - High‑dose salicylates (enhance hypoglycemic effect).

Use with caution: - Beta‑blockers (mask hypoglycemia symptoms). - Thiazide diuretics (may impair glucose control). - ACE inhibitors or ARBs (monitor renal function). - Antidepressants like SSRIs (potential additive effect on blood sugar).